Gabriel Hortobagyi joins Galena SAB
This article was originally published in Scrip
Oncology-focused Galena Biopharma has elected industry veteran Dr Gabriel Hortobagyi to its scientific advisory board. Dr Hortobagyi is a professor of medicine and chair of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center, where he also holds the Nellie B. Connallly chair in breast cancer research. In addition, he is senior editor for The Oncologist, associate editor for several other oncology publications and a board member of the American Society of Clinical Oncology.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.